Chronic Lyme disease is one of the most contested diagnoses in modern medicine. HBOT for Lyme is one of the most contested treatments. We walked the evidence from 1998 to today and found a research gap that has not closed.
The FDA has cleared HBOT for 13 specific uses. Lyme disease is not among them.
That does not make HBOT for Lyme illegal. It does make it off-label, uninsured, and unsupported by FDA review. We trace the evidence below.
The 1998 Fife study
The single most-cited trial for HBOT in Lyme is Fife et al. 1998. The trial enrolled 91 patients with chronic Lyme symptoms at the Texas A&M Hyperbaric Laboratory.
All patients got HBOT at 2.5 ATA for 60 sessions.
The study reported symptom improvement in 70% of patients. The protocol was 60 sessions over 12 to 18 weeks. The chamber was a hard-shell multiplace.
The study has three problems that limit how much weight we can put on it. First, there was no control group. Patients knew they were getting HBOT.
Second, the outcome measures were self-reported symptom scores. No blood work, no neurological exam, no objective marker.
Third, the trial has never been replicated. Twenty-seven years later, no comparable trial has been published.
For context, the HOPPS trial for TBI (2015) and the BIMA trial for PTSD (2018) used sham chambers and were larger. Lyme HBOT research has nothing comparable.
The biological hypothesis
HBOT advocates argue that Borrelia burgdorferi, the bacterium that causes Lyme, is sensitive to high oxygen environments. Lab work from the 1990s showed reduced spirochete survival in oxygen-rich settings (Austin 1995).
That is a real lab finding. It is also not the same as showing HBOT works for Lyme in humans. Many things kill bacteria in a Petri dish without helping patients.
The other mechanism advocates cite is anti-inflammatory effect. HBOT does reduce some markers of inflammation in controlled settings. The link to long-term Lyme symptoms is not established.
The bigger gap: there is no agreed-on biomarker for chronic Lyme that would let researchers measure whether HBOT actually clears infection. PCR for Borrelia DNA is unreliable after treatment.
What major institutions say
The Infectious Diseases Society of America (IDSA) does not recommend HBOT for Lyme. Their 2020 guidelines do not list it as a treatment option.
The CDC's Lyme treatment page does not mention HBOT. The standard treatment is oral doxycycline for 10-21 days.
The International Lyme and Associated Diseases Society (ILADS) takes a more permissive view of long-term and adjunctive treatments. Their 2014 guidelines mention HBOT as an option but flag the weak evidence.
Major academic Lyme research centers — Johns Hopkins, Columbia, Tufts — do not promote HBOT as a treatment. Their published work focuses on extended antibiotics, immune modulation, and post-treatment Lyme disease syndrome (PTLDS) as a distinct clinical entity.
The contrast with the off-label HBOT market is sharp. We unpack this pattern in our institutional silence on HBOT analysis.
What chronic Lyme HBOT clinics offer
Most clinics offering HBOT for Lyme run a 40 to 60 session hard-shell protocol at 2.0-2.4 ATA. Some run 1.5 ATA. A few high-end longevity clinics promote 60-session protocols for general "chronic conditions" that pull in Lyme patients.
Per-session pricing usually runs $250 to $500. A full course typically costs $10,000 to $30,000 out of pocket. Insurance does not cover it.
A few clinics market mild HBOT at 1.3 ATA for Lyme. The mechanistic case for 1.3 ATA against bacterial infection is weaker than for 2.0+ ATA, given the smaller arterial oxygen rise.
Our comparison of mild vs medical HBOT lays out where 1.3 ATA evidence holds up and where it does not.
What patients report
In Lyme advocacy communities, HBOT has a strong following. Patient testimonials describe symptom relief, especially for fatigue and cognitive fog.
We take patient experience seriously. We also note that placebo effect in chronic Lyme studies tends to run high. The Klempner 2001 trial of extended antibiotics for chronic Lyme found ~35% improvement in the placebo arm.
That means any intervention without a control group will show "benefit" in a third of patients — including saline, a sugar pill, or soft-shell HBOT at 1.3 ATA.
The Fife 1998 study showed 70% improvement. Subtract the expected placebo response and the effect size shrinks substantially. We cannot do that subtraction with confidence because Fife had no control arm.
Risks of HBOT for Lyme patients
HBOT carries real risks. The most common is ear barotrauma, which affects roughly 2% of sessions (Heyboer 2017).
Oxygen toxicity seizures are rare but serious. The risk rises with longer sessions and higher pressures.
Chamber fire is the catastrophic risk. The FDA issued a 2021 healthcare provider letter on fire-safety failures at non-medical sites.
For Lyme patients with autonomic dysfunction or postural orthostatic tachycardia syndrome (POTS) — common in chronic Lyme — pressure changes can trigger episodes. Discuss this with your treating physician before starting.
For more on side effects, see our HBOT safety overview.
How to evaluate a clinic offering HBOT for Lyme
A few questions cut through marketing claims.
What is the chamber make and model? Look up the K-number on openFDA.
Hard-shell chambers from Sechrist Industries and Perry Baromedical are the medical-grade options. Soft-shell OxyHealth or Summit to Sea models run at 1.3 ATA.
What pressure does the protocol use? Higher pressure (2.0+ ATA in Sechrist or Perry Baromedical hard-shells) has the most biological plausibility for an infection-based hypothesis. 1.3 ATA in OxyHealth or Summit to Sea soft-shells has weaker mechanistic backing.
Note that Restore Hyper Wellness sites only run soft-shell 1.3 ATA chambers and do not market a clinical Lyme protocol.
Is the clinic UHMS-accredited? Use the UHMS directory to verify. UHMS-accredited clinics rarely accept off-label Lyme patients because their FDA-approved wound work fills capacity.
What outcome measures will the clinic use? Symptom diaries are subjective. Ask whether any blood work or functional testing is included.
What is the total cost? Multiply the per-session rate by the protocol length before committing.
A note on Aviv Clinics
Aviv Clinics does not specifically market a "Lyme protocol." Its 60-session hyperbaric program is marketed for general aging and chronic condition recovery, and some Lyme patients enroll.
The protocol costs roughly $50,000. The supporting research is from the Sagol Center in Israel (Hadanny et al. 2020) and focuses on cognitive aging, not Lyme.
There is no published Aviv-specific trial for Lyme outcomes. The marketing implies broad chronic-disease benefit; the evidence is for a different patient population.
We walk through the Aviv evidence-marketing gap in our Aviv evidence-vs-marketing analysis.
What better research would look like
A modern HBOT for Lyme trial would need to include several things missing from Fife 1998.
A sham control arm. Patients would be randomized to real HBOT (2.0+ ATA) or sham (1.0 ATA or near-atmospheric). They and the assessors would be blinded.
Objective outcomes. Quality of life scales like SF-36, plus biomarkers — cytokine panels, neurocognitive testing, perhaps Lyme-specific markers if they become validated.
Adequate sample size. The HOPPS and BIMA TBI trials enrolled 71 and 71 patients respectively. A Lyme trial would need similar or larger.
No such trial is currently registered on ClinicalTrials.gov for HBOT in Lyme disease as of 2026. The research gap persists.
Bottom line
The evidence base for HBOT in Lyme disease is one small uncontrolled study from 1998 and a lot of patient testimonials. That is not nothing — but it is well below the bar for a $10,000-$30,000 out-of-pocket treatment.
If you are considering HBOT for Lyme, read the Fife paper. Read the IDSA guidelines. Talk to a Lyme specialist outside the clinic recommending the protocol.
If you do proceed, choose a UHMS-accredited or physician-led hard-shell program. Avoid clinics that promise cures or guarantee results. The honest answer is: we do not know if HBOT helps Lyme, and current research does not let us know.
Related Reading
- HBOT for ADHD: what the evidence actually shows
- HBOT for long COVID: Shamir RCT detailed analysis
- Institutional silence on HBOT
- Aviv Clinics: evidence vs marketing
- Mild HBOT vs medical HBOT
Frequently asked questions
Is HBOT FDA-approved for Lyme disease?
No. The FDA has cleared HBOT for 13 specific uses; Lyme is not among them. All use of HBOT for Lyme is off-label.
Does insurance cover HBOT for Lyme?
No. No major US insurer covers HBOT for Lyme disease. Patients pay out of pocket, typically $10,000 to $30,000 for a 40-60 session protocol.
How strong is the evidence for HBOT in Lyme?
Weak. The largest study is Fife et al. 1998, 91 patients, no control group. No modern randomized controlled trial exists. The IDSA does not recommend HBOT for Lyme.
Do major Lyme research centers offer HBOT?
No. Johns Hopkins, Columbia, and Tufts Lyme programs do not offer or recommend HBOT. Their research focuses on extended antibiotics and immune modulation.
What is post-treatment Lyme disease syndrome (PTLDS)?
PTLDS is the medical term for persistent symptoms after standard Lyme treatment. The CDC recognizes it. HBOT is not standard treatment for it. See the CDC PTLDS page for details.
Medical disclaimer: This article is informational and does not constitute medical advice. HBOT carries real risks including ear barotrauma, oxygen toxicity, and chamber fire. Discuss any HBOT plan with a doctor trained in undersea and hyperbaric medicine and an infectious disease specialist before starting. The FDA has cleared HBOT for 13 specific uses; Lyme disease is not among them, and use of HBOT for Lyme is off-label.
-- The HBOT Finder Team